469 related articles for article (PubMed ID: 21609270)
1. Current status of Chagas disease chemotherapy.
Guedes PM; Silva GK; Gutierrez FR; Silva JS
Expert Rev Anti Infect Ther; 2011 May; 9(5):609-20. PubMed ID: 21609270
[TBL] [Abstract][Full Text] [Related]
2. Chagas disease: Present status of pathogenic mechanisms and chemotherapy.
Maya JD; Orellana M; Ferreira J; Kemmerling U; López-Muñoz R; Morello A
Biol Res; 2010; 43(3):323-31. PubMed ID: 21249304
[TBL] [Abstract][Full Text] [Related]
3. Side effects of benznidazole as treatment in chronic Chagas disease: fears and realities.
Viotti R; Vigliano C; Lococo B; Alvarez MG; Petti M; Bertocchi G; Armenti A
Expert Rev Anti Infect Ther; 2009 Mar; 7(2):157-63. PubMed ID: 19254164
[TBL] [Abstract][Full Text] [Related]
4. [Treatment of Trypanosoma cruzi infection in the indeterminate phase: experience and current guidelines in Argentina].
Sosa Estani S; Segura EL
Medicina (B Aires); 1999; 59 Suppl 2():166-70. PubMed ID: 10668259
[TBL] [Abstract][Full Text] [Related]
5. [Treatment of Chagas' disease].
Apt W
Rev Med Chil; 1985 Feb; 113(2):162-6. PubMed ID: 3936147
[No Abstract] [Full Text] [Related]
6. Nifurtimox chemotherapy: collateral effects in treated Trypanosoma cruzi infected patients.
Murcia L; Carrilero B; Albajar Viñas P; Segovia M
Rev Esp Quimioter; 2012 Mar; 25(1):74-5. PubMed ID: 22488545
[No Abstract] [Full Text] [Related]
7. Antitrypanosomal therapy for chronic Chagas' disease.
Bern C
N Engl J Med; 2011 Jun; 364(26):2527-34. PubMed ID: 21714649
[No Abstract] [Full Text] [Related]
8. Side effects of benznidazole treatment in a cohort of patients with Chagas disease in non-endemic country.
Carrilero B; Murcia L; Martínez-Lage L; Segovia M
Rev Esp Quimioter; 2011 Sep; 24(3):123-6. PubMed ID: 21947093
[TBL] [Abstract][Full Text] [Related]
9. American trypanosomiasis (Chagas disease).
Rassi A; Rassi A; Marcondes de Rezende J
Infect Dis Clin North Am; 2012 Jun; 26(2):275-91. PubMed ID: 22632639
[TBL] [Abstract][Full Text] [Related]
10. Chagas disease. American trypanosomiasis.
Kirchhoff LV
Infect Dis Clin North Am; 1993 Sep; 7(3):487-502. PubMed ID: 8254156
[TBL] [Abstract][Full Text] [Related]
11. Trypanocidal drugs for late-stage, symptomatic Chagas disease (Trypanosoma cruzi infection).
Vallejo M; Reyes PP; Martinez Garcia M; Gonzalez Garay AG
Cochrane Database Syst Rev; 2020 Dec; 12(12):CD004102. PubMed ID: 33305846
[TBL] [Abstract][Full Text] [Related]
12. Toxic side effects of drugs used to treat Chagas' disease (American trypanosomiasis).
Castro JA; de Mecca MM; Bartel LC
Hum Exp Toxicol; 2006 Aug; 25(8):471-9. PubMed ID: 16937919
[TBL] [Abstract][Full Text] [Related]
13. [Allopurinol in the treatment of chronic Chagas' disease].
Meirovich CI; Montrull HL; Gallerano RH; Sosa RR
Arq Bras Cardiol; 1985 Sep; 45(3):217-23. PubMed ID: 3939099
[No Abstract] [Full Text] [Related]
14. Treatment of experimental chronic chagas disease with trifluralin.
Zaidenberg A; Luong T; Lirussi D; Bleiz J; Del Buono MB; Quijano G; Drut R; Kozubsky L; Marron A; Buschiazzo H
Basic Clin Pharmacol Toxicol; 2006 Apr; 98(4):351-6. PubMed ID: 16623857
[TBL] [Abstract][Full Text] [Related]
15. Tolerance and safety of nifurtimox in patients with chronic chagas disease.
Jackson Y; Alirol E; Getaz L; Wolff H; Combescure C; Chappuis F
Clin Infect Dis; 2010 Nov; 51(10):e69-75. PubMed ID: 20932171
[TBL] [Abstract][Full Text] [Related]
16. Potential new clinical therapies for Chagas disease.
Bustamante JM; Tarleton RL
Expert Rev Clin Pharmacol; 2014 May; 7(3):317-25. PubMed ID: 24716790
[TBL] [Abstract][Full Text] [Related]
17. Nifurtimox therapy for Chagas disease does not cause hypersensitivity reactions in patients with such previous adverse reactions during benznidazole treatment.
Pérez-Molina JA; Sojo-Dorado J; Norman F; Monge-Maillo B; Díaz-Menéndez M; Albajar-Viñas P; López-Vélez R
Acta Trop; 2013 Aug; 127(2):101-4. PubMed ID: 23583863
[TBL] [Abstract][Full Text] [Related]
18. Nifurtimox versus benznidazole or placebo for asymptomatic Trypanosoma cruzi infection (Equivalence of Usual Interventions for Trypanosomiasis - EQUITY): study protocol for a randomised controlled trial.
Villar JC; Herrera VM; Pérez Carreño JG; Váquiro Herrera E; Castellanos Domínguez YZ; Vásquez SM; Cucunubá ZM; Prado NG; Hernández Y
Trials; 2019 Jul; 20(1):431. PubMed ID: 31307503
[TBL] [Abstract][Full Text] [Related]
19. Treatment with benznidazole during the chronic phase of experimental Chagas' disease decreases cardiac alterations.
Garcia S; Ramos CO; Senra JF; Vilas-Boas F; Rodrigues MM; Campos-de-Carvalho AC; Ribeiro-Dos-Santos R; Soares MB
Antimicrob Agents Chemother; 2005 Apr; 49(4):1521-8. PubMed ID: 15793134
[TBL] [Abstract][Full Text] [Related]
20. Assessing antibody decline after chemotherapy of early chronic Chagas disease patients.
Murphy N; Cardinal MV; Bhattacharyya T; Enriquez GF; Macchiaverna NP; Alvedro A; Freilij H; Martinez de Salazar P; Molina I; Mertens P; Gilleman Q; Gürtler RE; Miles MA
Parasit Vectors; 2021 Oct; 14(1):543. PubMed ID: 34670602
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
